Skip to main content
. 2022 Dec 14;22(1):e13754. doi: 10.1111/acel.13754

FIGURE 2.

FIGURE 2

NEV biomarkers in response to oral nicotinamide riboside supplementation. (a) Alzheimer's disease biomarkers. (b) Canonical insulin/Akt signaling mediators. (c) Alternative MAPK insulin signaling biomarkers. Two‐tailed paired ttest was used for all analyses; horizontal bars depict mean; error bars depict SEM. * indicates significance >0.05.